Germany’s CureVac Raises $450m While Announcing $180.3m Deal with GSK to Partner up on mRNA-based Vaccine Co-Development, Manufacturing & Commercialization

Germany’s CureVac Raises $450m While Announcing $180.3m Deal with GSK to Partner up on mRNA-based Vaccine Co-Development, Manufacturing & Commercialization

Germany-based CureVac, the global biopharmaceutical company developing novel transformative medicines based on messenger ribonucleic acid (“mRNA), including a high potential COVID-19 vaccine candidate, just announced the closing it its follow-on public offering of 5 million common shares at a public offering price of $90 per common share, totaling a financing of approximately $450 million. Moreover, the company just announced a deal with GlaxoSmithKline (GSK) to develop next generation mRNA COVID-19 vaccines. In this new collaboration worth at least €150 million, the two leverage existing relationships to develop what they classify as the next generation of mRNA-based vaccines for COVID-19 with a potential for a multi-valent approach to addressing multiple emerging variants in one vaccine. As part of this deal, GSK will support the production of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate known as CVnCoV in 2021.

Raising Lots of Money

It’s been a whirlwind for CureVac as the company worked as a syndicate of investment banks to raise nearly half a billion dollars. Investment banks included BofA Securities, Jeffries and Evercore ISI (joint ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee